Fig. 2From: An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancerClinical outcomes. A-B Kaplan Meyer describing progression-free (A) and overall survival (B) in the intention-to-treat population. C Best change from baseline in size of target lesions in evaluable patientsBack to article page